ANI Pharmaceuticals is headquartered in Baudette, US

ANI Pharmaceuticals has an office in Baudette

Baudette, US (HQ)

210 Main St W

Baudette, US

455 Idc Rd Sw

ANI Pharmaceuticals's revenue was reported to be $36.6 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 36.6 m |

## Gross profit (Q1, 2017) | 20.2 m |

## Gross profit margin (Q1, 2017), % | 55% |

## Net income (Q1, 2017) | 1.2 m |

## EBIT (Q1, 2017) | 4.6 m |

## Market capitalization (25-Jul-2017) | 577.5 m |

## Cash (31-Mar-2017) | 10.8 m |

ANI Pharmaceuticals's current market capitalization is $577.5 m.

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 30.1 m | 56 m | 76.3 m | 128.6 m |

## Revenue growth, % | 86% | 36% | 69% | |

## Cost of goods sold | 10 m | 11.5 m | 12.7 m | 48.8 m |

## Gross profit | 20.1 m | 44.5 m | 63.6 m | 79.8 m |

## Gross profit Margin, % | 67% | 80% | 83% | 62% |

## R&D expense | 2.9 m | |||

## Operating expense total | 19.2 m | 24.5 m | 30.9 m | 108.5 m |

## EBIT | 898 k | 20 m | 32.7 m | 20.1 m |

## EBIT margin, % | 3% | 36% | 43% | 16% |

## Interest expense | 467 k | 787 k | 11 m | 11.3 m |

## Net Income | 301 k | 28.7 m | 15.4 m | 3.9 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 6.6 m | 17.4 m | 18.8 m | 19.5 m | 20 m | 20.6 m | 31.3 m | 38.5 m | 36.6 m |

## Cost of goods sold | 2.1 m | 3.1 m | 2.8 m | 3.1 m | 3.3 m | 3.4 m | 11.8 m | 16.7 m | 16.4 m |

## Gross profit | 4.5 m | 14.3 m | 16 m | 16.4 m | 16.7 m | 17.1 m | 19.5 m | 21.9 m | 20.2 m |

## Gross profit Margin, % | 68% | 82% | 85% | 84% | 84% | 83% | 62% | 57% | 55% |

## R&D expense | 851 k | 883 k | 403 k | 995 k | 815 k | 966 k | 764 k | 1 m | 1.6 m |

## General and administrative expense | 5.4 m | 4.1 m | 4.8 m | 5.6 m | 5.4 m | ||||

## Operating expense total | 6.3 m | 4.9 m | 5.2 m | 6.5 m | 6.2 m | 966 k | 764 k | 1 m | 1.6 m |

## EBIT | (2.5 m) | 9.6 m | 8.5 m | 5.7 m | 5.2 m | 7.9 m | 4.6 m | ||

## EBIT margin, % | (37%) | 51% | 42% | 28% | 17% | 21% | 13% | ||

## Interest expense | (2.7 m) | (2.8 m) | (2.8 m) | (2.9 m) | (2.9 m) | ||||

## Pre tax profit | 6.9 m | 5.7 m | 2.9 m | 2.4 m | 5 m | 1.7 m | |||

## Income tax expense | (2.5 m) | (1.1 m) | (1.5 m) | (1.2 m) | (2.5 m) | (523 k) | |||

## Net Income | 6.7 m | 4.4 m | 3.6 m | 4.6 m | 1.3 m | 1.1 m | 2.5 m | 1.2 m |

- Source: SEC Filings

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 11.1 m | 169 m | 154.7 m | 27.4 m |

## Accounts Receivable | 12.5 m | 17.3 m | 21.9 m | 45.9 m |

## Inventories | 580 k | 1.1 m | 1.5 m | 26.2 m |

## Current Assets | 27.7 m | 203.5 m | 192.6 m | 103 m |

## PP&E | 4.5 m | 5.2 m | 7.1 m | 11 m |

## Goodwill | 1.8 m | 1.8 m | 1.8 m | 1.8 m |

## Total Assets | 44.5 m | 263.7 m | 285.3 m | 322.9 m |

## Accounts Payable | 1.4 m | 2.7 m | 2.1 m | 3.4 m |

## Current Liabilities | 3.5 m | 13.2 m | 11.8 m | 31.9 m |

## Total Liabilities | 153.2 m | |||

## Additional Paid-in Capital | 89.5 m | 159.5 m | 164.4 m | 172.6 m |

## Retained Earnings | (48.5 m) | (19.7 m) | (4.4 m) | (2.9 m) |

## Total Equity | 41 m | 139.8 m | 160.1 m | 169.6 m |

## Financial Leverage | 1.1 x | 1.9 x | 1.8 x | 1.9 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 53 m | 35.1 m | 165.6 m | 166.7 m | 150.9 m | 77.7 m | 15 m | 16.2 m | 10.8 m |

## Inventories | 5.9 m | 7.3 m | 10.7 m | 12.7 m | 13.7 m | 13.9 m | 25.1 m | 28.3 m | 45.9 m |

## Current Assets | 67.2 m | 57.6 m | 203 m | 208.9 m | 197.5 m | 116.6 m | 79.8 m | 95.5 m | 107 m |

## PP&E | 4.6 m | 5 m | 5.3 m | 5.2 m | 5.8 m | 8.4 m | 8.9 m | 9.7 m | 12.9 m |

## Goodwill | 1.8 m | 1.8 m | 1.8 m | 1.8 m | 1.8 m | 1.8 m | 1.8 m | 1.8 m | 1.8 m |

## Total Assets | 95.4 m | 107.6 m | 266 m | 270.1 m | 283.3 m | 291.6 m | 308 m | 319.4 m | 357.1 m |

## Accounts Payable | 1.7 m | 3.1 m | 2.3 m | 1.3 m | 2.6 m | 3 m | 5 m | 4.7 m | 4.8 m |

## Current Liabilities | 3.8 m | 8.1 m | 9.1 m | 6.9 m | 12.2 m | 16.2 m | 24.7 m | 30.5 m | 32.4 m |

## Additional Paid-in Capital | 139.1 m | 140.2 m | 160.1 m | 161.4 m | 163.1 m | 165.7 m | 168.2 m | 170.7 m | 174 m |

## Retained Earnings | (47.5 m) | (40.7 m) | (15.4 m) | (11.8 m) | (7.2 m) | (5.5 m) | (4.4 m) | (1.8 m) | (1.8 m) |

## Total Equity | 91.6 m | 99.5 m | 144.7 m | 149.5 m | 155.9 m | 160.2 m | 163.8 m | 168.8 m | 172.2 m |

## Financial Leverage | 1 x | 1.1 x | 1.8 x | 1.8 x | 1.8 x | 1.8 x | 1.9 x | 1.9 x | 2.1 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | 301 k | 28.7 m | 15.4 m | 3.9 m |

## Depreciation and Amortization | 1.1 m | 3.9 m | 6.9 m | 22.3 m |

## Accounts Receivable | (7.1 m) | (4.8 m) | (4.6 m) | (24 m) |

## Inventories | (708 k) | (3.5 m) | (314 k) | (647 k) |

## Accounts Payable | (565 k) | 225 k | (1 m) | 1.1 m |

## Cash From Operating Activities | 11.1 m | 157.9 m | (14.4 m) | 27.5 m |

## Purchases of PP&E | (191 k) | (1.1 m) | (2.2 m) | (4.6 m) |

## Cash From Investing Activities | 20.3 m | (35.8 m) | (32.7 m) | (154.1 m) |

## Interest Paid | 250 k | 4.2 m | ||

## Income Taxes Paid | 147 k | 13.3 m | 9.5 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | 6.7 m | 4.4 m | 3.6 m | 4.6 m | 1.3 m | 1.1 m | 2.5 m | 1.2 m | |

## Depreciation and Amortization | 706 k | 1.2 m | 1.3 m | 1.4 m | 2 m | 4.6 m | 6 m | 6 m | 6.7 m |

## Accounts Payable | 1.7 m | 3.1 m | 2.3 m | 1.3 m | 2.6 m | 3 m | 5 m | 4.7 m | 4.8 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 256.1 k |

## Financial Leverage | 2.1 x |